Accrued long term co promotion liability current.

No definition available.

Name:	fgen_AccruedLongTermCoPromotionLiabilityCurrent
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Accrued long term co promotion liability non current.

+ References

No definition available.

+ Details

Name:	fgen_AccruedLongTermCoPromotionLiabilityNonCurrent
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Co-promotion expenses.

+ References

No definition available.

+ Details

Name:	fgen_CoPromotionExpenses
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of aggregate consideration receivable under collaborative arrangement.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAggregateConsideration
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative arrangement aggregate consideration for milestone and upfront payments.

+ References

No definition available.

+ Details

Name:	fgen_CollaborativeArrangementAggregateConsiderationForMilestoneAndUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Commercial sales and other events milestone.

+ References

No definition available.

+ Details

Name:	fgen_CommercialSalesAndOtherEventsMilestone
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of milestone payments related to commercial sales under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	fgen_CommercialSalesMilestone
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development milestone payment received.

+ References

No definition available.

+ Details

Name:	fgen_DevelopmentMilestonePaymentReceived
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Estimated joint development extended service period.

+ References

No definition available.

+ Details

Name:	fgen_EstimatedJointDevelopmentExtendedServicePeriod
Namespace Prefix:	fgen_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

- Definition

Historical co-promotion costs.

+ References

No definition available.

+ Details

Name:	fgen_HistoricalCoPromotionCosts
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	fgen_PotentialMilestones
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.

+ References

No definition available.

+ Details

Name:	fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.

+ References

No definition available.

+ Details

Name:	fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Reversal of accrued co-promotion expenses.

+ References

No definition available.

+ Details

Name:	fgen_ReversalOfAccruedCoPromotionExpenses
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Transaction price allocated to performance obligations.

+ References

No definition available.

+ Details

Name:	fgen_TransactionPriceAllocatedToPerformanceObligations
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(7)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320

+ Details

Name:	us-gaap_Supplies
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DeferredApprovalMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_NewDrugApplicationSubmissionMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)		1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
	Jul. 30, 2013	Apr. 30, 2020	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2015	Mar. 31, 2020	Jun. 30, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unbilled contract asset			$ 180,000,000	$ 0	$ 0
Accrued long-term co-promotion expenses			53,071,000	26,344,000	26,344,000
Accrued long term co promotion liability current				14,800,000	14,800,000
AstraZeneca Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price and allocated to performance obligations								$ 50,000,000.0
Revenue during period from performance obligations			42,400,000	600,000	600,000
Unbilled contract asset							$ 50,000,000.0
Historical co-promotion costs				0	0
Accrued long term co promotion liability current				14,800,000	14,800,000
AstraZeneca Agreements [Member] \| Selling, General and Administrative Expenses [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reversal of accrued co-promotion expenses				84,400,000
Co-promotion expenses				8,800,000	14,800,000
AstraZeneca Agreements [Member] \| Other Noncurrent Liabilities
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued long-term co-promotion expenses				26,300,000	26,300,000
AstraZeneca Agreements [Member] \| U.S./RoW [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront, non-contingent, non-refundable and time-based payments	$ 374,000,000.0
Potential milestone payments	875,000,000.0
Commercial sales milestone	325,000,000.0
Aggregate consideration received				439,000,000.0	$ 439,000,000.0
Unbilled contract asset			50,000,000.0
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Clinical and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	65,000,000.0
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	325,000,000.0
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Deferred Approval Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	160,000,000.0
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Development Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receipt of development milestone payment						$ 15,000,000.0
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| NDA Submission Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receipt of development milestone payment		$ 50,000,000.0
AstraZeneca Agreements [Member] \| China [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	348,500,000		22,000,000.0
Transaction price and allocated to performance obligations			$ 22,000,000.0
Estimated joint development extended service period					2024
Proceeds from upfront, non-contingent and non-refundable payments	28,200,000
Commercial sales and other events milestone	187,500,000
Aggregate consideration received for milestone and upfront payments				77,200,000	$ 77,200,000
Changes in revenue due to prior period adjustment of performance obligations				$ (2,000,000.0)
AstraZeneca Agreements [Member] \| China [Member] \| Clinical and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	15,000,000.0
AstraZeneca Agreements [Member] \| China [Member] \| Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments	$ 146,000,000.0